Unichem Lab receives USFDA acclaim for Apremilast Tablets

Unichem Lab receives USFDA acclaim for Apremilast Tablets

by admin- Friday, February 19th, 2021 04:46:34 PM

Unichem Laboratories acquired ANDA acclaim for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to marketplace a established version of Amgen’s Otezla (apremilast) Tablets.

Apremilast pills are indicated for the remedy of adult patients with mild to intense plaque psoriasis who are candidates for phototherapy or systemic remedy.

News Updates